In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM

被引:11
作者
de Graaff, M
Maliepaard, M
Pluim, D
Floot, BJG
Slaper-Cortenbach, ICM
Schellens, JHM
机构
[1] Netherlands Canc Inst, Dept Expt Therapy & Med Oncol, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Red Cross, Blood Transfus Serv, Cent Lab, NL-1066 CX Amsterdam, Netherlands
关键词
cellular uptake; CFU-GM; cytotoxic interactions; platinum drugs; taxanes;
D O I
10.1097/00001813-199902000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have designed and used an in vitro bone marrow cell culturing system for investigating pharmacodynamic interactions between platinum anti-cancer drugs and taxanes. With this system, in which the bone marrow progenitor cell CFU-GM is proliferating and differentiating into granulocytes and monocytes, we could show a strong antagonistic cytotoxicity of the combination carboplatin and Taxotere, in three different schedules, and of the combination cisplatin and Taxol, in two out of the three schedules tested. Modulation of intracellular platinum drug accumulation in granulocytes and monocytes does not seem to be a plausible explanation for the observed antagonism. In vitro coincubation of granulocytes/monocytes with the combination carboplatin and Taxotere did not reveal an effect of Taxotere on intracellular platinum accumulation. Although Taxol reduced intracellular cisplatin levels by 12%, this effect was not significantly different from the co-incubation of cisplatin with Cremophor EL, the solvent for paclitaxel in Taxol. The toxicity data obtained in this study seem to be in accordance with recent clinical trials where combination therapies with platinum drugs and taxanes resulted in marked reductions in myelosuppression in patients. Therefore, these types of assays could be useful as to the assessment of bone marrow toxicities of clinically important drug combinations, [(C) 1999 Lippincott Williams & Wilkins.].
引用
收藏
页码:213 / 218
页数:6
相关论文
共 19 条
[1]   Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group [J].
Bookman, MA ;
McGuire, WP ;
Kilpatrick, D ;
Keenan, E ;
Hogan, WM ;
Johnson, SW ;
ODwyer, P ;
Rowinsky, E ;
Gallion, HH ;
Ozols, RF .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1895-1902
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
Calvert A. Hilary, 1997, Seminars in Oncology, V24, P85
[4]   COMPUTERIZED QUANTITATION OF SYNERGISM AND ANTAGONISM OF TAXOL, TOPOTECAN, AND CISPLATIN AGAINST HUMAN TERATOCARCINOMA CELL-GROWTH - A RATIONAL APPROACH TO CLINICAL PROTOCOL DESIGN [J].
CHOU, TC ;
MOTZER, RJ ;
TONG, YZ ;
BOSL, GJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20) :1517-1524
[5]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[6]   Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL [J].
de Vos, AI ;
Nooter, K ;
Verweij, J ;
Loos, WL ;
Brouwer, E ;
de Bruijn, P ;
Ruijgrok, EJ ;
van der Burg, MEL ;
Stoter, G ;
Sparreboom, A .
ANNALS OF ONCOLOGY, 1997, 8 (11) :1145-1150
[7]  
HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134
[8]   Pharmacokinetics of paclitaxel and carboplat dose-escalating and dose-sequencing study in with non-small-cell long cancer [J].
Huizing, MT ;
Giaccone, G ;
vanWarmerdam, LJC ;
Rosing, H ;
Bakker, PJM ;
Vermorken, JB ;
Postmus, PE ;
vanZandwijk, N ;
Koolen, MGJ ;
Huinink, WWTB ;
vanderVijgh, WJF ;
Bierhorst, FJ ;
Lai, A ;
Dalesio, O ;
Pinedo, HM ;
Veenhof, CHN ;
Beijnen, JH .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :317-329
[9]   Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer [J].
Huizing, MT ;
vanWarmerdam, LJC ;
Rosing, H ;
Schaefers, MCW ;
Lai, A ;
Helmerhorst, TJM ;
Veenhof, CHN ;
Birkhofer, MJ ;
Rodenhuis, S ;
Beijnen, JH ;
tenBokkelHuinink, WW .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1953-1964
[10]  
LIEBMANN J, 1994, CANCER CHEMOTH PHARM, V33, P331